8-K: Akari Therapeutics Announces Leadership Changes and Portfolio Prioritization Following Peak Bio Merger Agreement

Akari Therapeutics has announced the departure of its CEO and COO, the appointment of an interim CEO, and a strategic portfolio prioritization following its merger agreement with Peak Bio.

Summary

• Akari Therapeutics has announced that Rachelle Jacques stepped down as President and CEO, effective May 1, 2024.
• Samir R. Patel, M.D., a board member, has been appointed as Interim President and CEO, also effective May 1, 2024.
• Melissa Bradford-Klug, the Chief Operating Officer, was terminated without cause, effective May 1, 2024.
• The company has amended its consulting agreement with Wendy DiCicco, the interim CFO, increasing her monthly fee to $40,000 for up to 80 hours of work, a 45% target bonus, a 10% transaction bonus upon the merger with Peak Bio, and a one-time grant of RSUs equal to 1% of outstanding shares.
• Akari and Peak Bio have completed a joint portfolio assessment and will prioritize Peak's ADC platform technology and Akari's PAS-nomacopan for Geographic Atrophy (GA).
• The combined company will suspend Akari's HSCT-TMA program and Peak Bio's PHP 303 program for Alpha 1 anti-trypsin deficiency.
• The merger between Akari and Peak Bio is expected to close by the third quarter of this year, with the combined entity operating as Akari Therapeutics, Plc.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with both positive strategic shifts and negative leadership changes. The focus on promising programs is encouraging, but the executive departures and program discontinuations create uncertainty.

Positives

• The company has a clear strategic direction post-merger, focusing on promising programs like the ADC platform and PAS-nomacopan for GA.
• The interim CEO, Dr. Patel, has extensive experience in life sciences and biotechnology.
• The consulting agreement with the interim CFO includes performance-based incentives, aligning her interests with the company's success.
• The prioritization of the ADC and PAS-nomacopan programs is expected to improve the company's ability to secure business development opportunities and funding.
• PAS-nomacopan has shown potential for less frequent dosing in animal models, which could be a competitive advantage.

Negatives

• The departure of the CEO and COO creates uncertainty in leadership.
• The termination of the HSCT-TMA and PHP 303 programs may result in lost potential.
• The company is relying on an interim CEO while searching for a permanent replacement.
• The merger is still subject to customary closing conditions and shareholder approval, which introduces some risk.

Risks

• The company faces risks related to cost reduction efforts, which may impact development activities.
• The merger may not be completed in the expected timeframe or at all.
• The company may not realize the anticipated benefits of the merger.
• There are risks associated with the development and commercialization of the prioritized programs.
• The company is subject to risks related to global and local political and economic conditions.

Future Outlook

The company will focus on advancing the ADC platform and PAS-nomacopan for GA, while seeking business development opportunities and funding. The merger with Peak Bio is expected to close by the third quarter of this year.

Management Comments

• The boards believe by prioritizing the ADC and PAS-nomacopan GA programs the post-closing combined company will be in the best position to secure business development opportunities and funding while continuing to advance these important programs, said Hoyoung Huh, M.D., Ph.D. Chairman, Peak Bio, and Ray Prudo, M.D. Chairman, Akari Therapeutics.

Industry Context

The focus on ADC technology aligns with the growing interest in targeted cancer therapies, while the development of PAS-nomacopan for GA addresses a significant unmet need in ophthalmology. The merger is part of a trend of consolidation in the biotech industry to combine resources and expertise.

Comparison to Industry Standards

• The development of ADC technology is comparable to companies like ImmunoGen and Seagen, which have successfully brought ADC therapies to market.
• The focus on Geographic Atrophy is similar to companies like Apellis and Iveric Bio, which have recently gained FDA approval for complement inhibitors in this space.
• The company's approach to bispecific inhibition of leukotriene B4 and complement with PAS-nomacopan is a unique approach compared to traditional complement inhibitors.
• The merger is similar to other biotech mergers aimed at combining complementary pipelines and technologies, such as the recent merger between Jazz Pharmaceuticals and GW Pharmaceuticals.

Management Changes

Stakeholder Impact

• Shareholders may experience volatility due to the leadership changes and strategic shifts.
• Employees may be affected by the reduction in force and program discontinuations.
• Customers and partners may be impacted by the changes in the company's focus and pipeline.
• Creditors may be affected by the financial implications of the merger and restructuring.

Next Steps

• The company will continue the search for a new President and Chief Executive Officer.
• The company will work towards closing the merger with Peak Bio by the third quarter of this year.
• The company will continue IND enabling development of PAS-nomacopan for GA.
• The company will continue business development activities for the ADC platform.
• The company will work with the FDA to define the best path forward for the HSCT-TMA technology.

Key Dates

Keywords

merger, biotechnology, ADC, PAS-nomacopan, leadership change, portfolio prioritization, geographic atrophy, oncology, clinical trials, interim CEO